References in periodicals archive ?
a variety of markers have been developed, and the following have been approved by the Food and Drug Administration to monitor patients with bladder cancer: bladder tumor antigen (BTA), fibrin/fibrinogen degradation product (FDP), and nuclear matrix protein (NMP22).
A comparison of urinary nuclear matrix protein-22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family [Abstract].